A Georgia highway worker and father of four lost his eyesight after nearly a year of using popular GLP-1 weight loss injections, joining a growing number of patients filing lawsuits against the manufacturer for allegedly failing to warn about severe vision risks.
Sudden Blindness After Routine Treatment
Ed Gillen woke up one Saturday morning with what appeared to be a simple floater in his eye. Within days, the Georgia state highway worker and youth softball coach found himself completely blind. Doctors diagnosed him with NAION, an eye stroke condition they called “Ozempic blindness.” The rapid progression left no warning signs and caused no pain before his vision vanished entirely. Gillen now requires a walking stick to navigate daily life.
“I was very good at my job. And now I got to learn this, a new job of being blind,” Gillen said. He had been taking the GLP-1 shots for almost a year to manage his A1-C diabetes levels, never suspecting the medication could cost him his sight. The father of four emphasized that no warnings about potential vision loss accompanied his prescription or treatment information.
Lawsuits Mount Against Drug Manufacturer
Gillen filed a lawsuit alongside fellow plaintiff Diane Wirth, who also lost her vision after using the medication. Their cases join multiple others now consolidated before a Philadelphia judge, all alleging that Novo-Nordisk failed to properly disclose the rare but devastating side effect. Wirth stated she would never have taken the drug if vision loss had been listed as a possible complication.
The pharmaceutical company conducted its own internal study and reported finding no increased risk of vision problems associated with the medication. However, patients and their legal teams argue the company should have been more transparent about NAION cases appearing in medical reports. The lawsuits seek damages for life-altering injuries that have left working professionals unable to perform their jobs or maintain their previous quality of life.
Long Legal Battle Ahead
The consolidated cases could take years to resolve through the court system. Both Gillen and Wirth face permanent blindness while awaiting potential compensation or accountability from the manufacturer. The legal proceedings will examine whether adequate warnings existed about vision complications and whether the company prioritized profits over patient safety. Legal experts indicate these cases could set precedents for how pharmaceutical companies disclose rare but serious side effects for widely-prescribed medications that millions of Americans currently use for weight management and diabetes control.